Flavoxate

Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors.

Flavoxate
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa682706
ATC code
Identifiers
IUPAC name
  • 2-(1-piperidyl)ethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.035.745
Chemical and physical data
FormulaC24H25NO4
Molar mass391.467 g·mol−1
3D model (JSmol)
SMILES
  • O=C(OCCN1CCCCC1)c4cccc2c4O/C(=C(\C2=O)C)c3ccccc3
InChI
  • InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3 Y
  • Key:SPIUTQOUKAMGCX-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

Clinical uses

Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin)(india), Genurin (by Recordati, Italy) in Italy and KSA, Uritac by El Saad company in Syria, under the name Bladderon by Nippon Shinyaku of Japan, or Bladuril in Chile, Utispas ( Apex Pharma) in Nepal.

Flavoxate is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Side effects

Flavoxate is generally well tolerated, but can potentially cause vomiting, upset stomach, dry mouth or throat, blurred vision, eye pain,[1] and increased sensitivity of the eyes to light.

Contraindications

Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

References

  1. Mohammed ZS, Simi ZU, Tariq SM, Ali KR (November 2008). "Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate". British Journal of Clinical Pharmacology. 66 (5): 726–7. doi:10.1111/j.1365-2125.2008.03254.x. PMC 2661991. PMID 18754848.

Further reading

  • Brenner GN (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6.
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4.
  • "Flavoxate". PubMed Health. U.S. National Library of Medicine, National Institutes of Health.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.